0001179110-17-014968.txt : 20171205
0001179110-17-014968.hdr.sgml : 20171205
20171205185205
ACCESSION NUMBER: 0001179110-17-014968
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20171127
FILED AS OF DATE: 20171205
DATE AS OF CHANGE: 20171205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bolgiano Elizabeth Scott
CENTRAL INDEX KEY: 0001723774
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 171240811
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
3
1
edgar.xml
FORM 3 -
X0206
3
2017-11-27
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001723774
Bolgiano Elizabeth Scott
C/O AMAG PHARMACEUTICALS, INC.
1100 WINTER STREET
WALTHAM
MA
02451
0
1
0
0
Chief Human Resources Officer
Common Stock
42155
D
Stock Option (Right to Buy)
23.93
2024-01-06
Common Stock
45000
D
Stock Option (Right to Buy)
21.13
2024-02-27
Common Stock
21094
D
Stock Option (Right to Buy)
49.46
2025-02-26
Common Stock
10000
D
Stock Option (Right to Buy)
25.18
2026-03-01
Common Stock
12500
D
Stock Option (Right to Buy)
23.75
2027-02-23
Common Stock
12000
D
Includes 23,618 shares of unvested restricted stock units ("RSU"), each of which represents a contingent right to receive one share of common stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
Grant of stock options pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended, the "Plan"). The initial option award provided for the vesting of four equal annual installments with the final vesting date to occur on January 6, 2018.
Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on February 27, 2018.
Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on February 26, 2019.
Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on March 1, 2020.
Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on February 23, 2021.
Nancy R. Smith, attorney-in-fact
2017-12-05
EX-24
2
powerofattorney.txt
POWER OF ATTORNEY
For Executing Forms 3, 4 and 5
Know all by these present,that the undersigned hereby
constitutes and appoints each of Joseph Vittiglio and Nancy Smith,
signing singly, his true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned,in the
undersigneds capacity as an officer and/or director of
AMAG Pharmaceuticals, Inc., or the Company, Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934,
as amended and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
the execution of any such Forms 3, 4 and 5 and the timely filing
of such forms with the United States Securities and Exchange
Commission and any other authority; and
(3) take any other action of any type whatsoever in connection
with the foregoing which,in the opinion of such attorney-in-fact
may be of benefit to,in the best interest of,or legally required
by,the undersigned,it being understood that the documents
executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact
may approve in his discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform all and every act and thing
whatsoever requisite, necessary and proper to be done in the
exercise of any of the rights and powers herein granted,as fully
to all intents and purposes as the undersigned might or could do
if personally present,with full power of substitution or revocation
hereby ratifying and confirming all that such attorney-in-fact, or
his substitute or substitutes, shall lawfully do or cause to be done
by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming,
any of the undersigneds responsibilities to comply with Section 16
of the Securities Exchange Act of 1934, as amended.
This Power of Attorney replaces in their entirety any and all
prior powers of attorney executed by the undersigned with respect
to the subject matters set forth herein, including any powers of
attorney previously filed with the Securities and Exchange
Commission. This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file
Forms 3, 4 and 5 with respect to the undersigneds holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed this 20th day of November 2017.
Signed: /s/ Elizabeth Scott Bolgiano
Please Print: Elizabeth Scott Bolgiano